Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).Kristina M. Jordahl, Safiyyah Ziyad, Wei-Ming Kao et al.|Journal of Clinical Oncology|2025Cited by 1
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Jesús G. Berdeja, Hongxiang Hu et al.|Blood|2026Cited by 1
Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)Susan Bal, Jesús G. Berdeja, Myo Htut et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior RegimensSusan Bal, Omar Nadeem, Myo Htut et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)Safiyyah Ziyad, Jesús G. Berdeja, Kristina M. Jordahl et al.|Blood|2025Cited by 0